EP Patent

EP4501409A2 — Treatment of b-cell malignancies by a combination jak and pi3k inhibitor

Assigned to Incyte Holdings Corp · Expires 2025-02-05 · 1y expired

What this patent protects

This invention relates to methods of treating B-cell malignancies using a combination of inhibitors of JAK1 and/or JAK2 and inhibitors of PI3Kδ.

USPTO Abstract

This invention relates to methods of treating B-cell malignancies using a combination of inhibitors of JAK1 and/or JAK2 and inhibitors of PI3Kδ.

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: EP4501409A2
Jurisdiction: EP
Classification: —
Expires: 2025-02-05
Drug substance claim: No
Drug product claim: No
Assignee: Incyte Holdings Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.